%0 Journal Article %T The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma %A Di He %A Qin Xu %A Ming Yan %A Ping Zhang %A Xiaojian Zhou %A Zhiyuan Zhang %A Wenhu Duan %A Laiping Zhong %A Dongxia Ye %A Wantao Chen %J BMC Cancer %D 2009 %I BioMed Central %R 10.1186/1471-2407-9-343 %X Three human oral squamous cell carcinoma cell lines, Tca8113, TSCC and NT, were treated with GA alone, celastrol alone or GA plus celastrol. Cytotoxicity was assessed by MTT assay. The rate of apoptosis was examined with annexin V/PI staining as well as transmission electronic microscopy in Tca8113 cells. The level of constitutive NF-kappa B activity in oral squamous cell carcinoma cell lines was determined by immunofluorescence assays and nuclear extracts and electrophoretic mobility shift assays (EMSAs) in vitro. To further investigate the role of NF-kappa B activity in GA and celastrol treatment in oral squamous cell carcinoma, we used the dominant negative mutant SR-I¦ÊB¦Á to inhibit NF-kappa B activity and to observe its influence on the effect of GA.The results showed that GA could inhibit the proliferation and induce the apoptosis of the oral squamous cell carcinoma cell lines and that the NF-kappa B pathway was simultaneously activated by GA treatment. The minimal cytotoxic dose of celastrol was able to effectively suppress the GA-induced NF-kappa B pathway activation. Following the combined treatment with GA and the minimal cytotoxic dose of celastrol or the dominant negative mutant SR-I¦ÊB¦Á, proliferation was significantly inhibited, and the apoptotic rate of Tca8113 cells was significantly increased.The combination of GA and celastrol has a synergistic antitumor effect. The effect can be primarily attributed to apoptosis induced by a decrease in NF-kappa B pathway activation. The NF-kappa B signaling pathway plays an important role in this process. Therefore, combining GA and celastrol may be a promising modality for treating oral squamous cell carcinoma.Despite improvements in surgery and radiation, the overall survival rate of patients with oral squamous cell carcinoma (OSCC) has not improved over the past two decades[1]. Chemotherapy (pre- or post-surgery) does not appear to be beneficial for local control and survival improvement in the patients with OSC %U http://www.biomedcentral.com/1471-2407/9/343